Activity, Motor Control & Coordination
Pain - Thermal Allodynia / Hyperalgesia
Pain - Spontaneous Pain - Postural Deficit
Pain - Mechanical Allodynia / Hyperalgesia
Anxiety & Depression Disorder
Learning/Memory - Attention - Addiction
Physiology & Respiratory Research
Metabolism - Food & Drink Intake
Pain
Central Nervous System (CNS)
Neurodegeneration
Sensory system
Motor control
Mood Disorders
Other disorders
Muscular system
Joints
Metabolism
Cross-disciplinary subjects
SFN2024: Meet our team in Chicago on booth #876 Authors
C Shan, X Xie, H Luo, AE Muruato, Y Liu, M Wakamiya
Lab
Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA
Journal
Nature Communications
Abstract
An important goal of the Zika virus (ZIKV) vaccine is to prevent a congenital syndrome in fetuses of pregnant women, but studies directly evaluating maternal vaccination for ZIKV are lacking. Here we report maternal vaccination using a live-attenuated ZIKV vaccine (3_UTR-delta10-LAV) in a pregnant mouse model. Maternal immunization with 3_UTR-delta10-LAV does not cause any adverse effects on pregnancy, fetal development, or offspring behavior. One maternal immunization fully protects dams against ZIKV infection and in utero transmission. Although neutralizing antibody alone is sufficient to prevent in utero transmission, a higher neutralizing titer is required to protect pregnant mice against in utero transmission than that required to protect non-pregnant mice against viral infection. The immunized dams transfer maternal antibodies to pups, which protect neonates against ZIKV infection. Notably, pregnancy weakens maternal T cell response to 3_UTR-delta10-LAV vaccination. Our results suggest that, besides vaccinating non-pregnant individuals, 3_UTR-delta10-LAV may also be considered for maternal vaccination.
BIOSEB Instruments Used:
Grip strength test (BIO-GS3)
